Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 9/20 | 0.45 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373568 | 0.90 | POLB (0.44) | CASP1SMN1; SMN2HSD17B10TSHRCASP7 | |
| SCHEMBL12373520 | 0.90 | CASP1 (0.39) | CASP1ITGAVSMN1; SMN2 | |
| SCHEMBL12373573 | 0.90 | CASP1 (0.41) | CASP1MRGPRX1ALPL | |
| SCHEMBL12373735 | 0.90 | MMP7 (0.43) | SMN1; SMN2ALPL | |
| SCHEMBL12373587 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2ALPL | |
| SCHEMBL12373501 | 0.89 | CYP1A2 (0.41) | CASP1ITGAVSMN1; SMN2HSD17B10TSHR | |
| SCHEMBL12373700 | 0.89 | FEN1 (0.39) | CASP1 | |
| SCHEMBL12373466 | 0.89 | POLB (0.40) | CASP1SMN1; SMN2 | |
| SCHEMBL12373591 | 0.89 | ALDH1A1 (0.38) | CASP1SMN1; SMN2 | |
| SCHEMBL12373547 | 0.89 | PGR (0.40) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | CASP1 1552/4885MRGPRX1 56/4885ITGAV 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.